Background: Despite improvements in perinatal care, bronchopulmonary dysplasia (BPD) in extremely premature infants has not decreased. Postnatal surfactant therapy provides symptomatic relief from respiratory distress syndrome, but does not translate into a reduction in BPD. Therefore, the search for effective interventions to prevent BPD continues. Objectives: Since PPAR-γ agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-γ agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone. Methods: One-day-old Sprague-Dawley rat pups were administered PGZ + B-YL via nebulization every 24 h for up to 72 h. The pups were exposed to either 21 or 95% O 2 , and then sacrificed. Their lungs were examined for markers of lung maturation (levels of PPAR-γ, SP-C and choline-phosphate cytidylyltransferase [CCT-α] and [ 3 H]triolein uptake) and injury repair (bronchoalveolar lavage cell count and protein content, and levels of LEF-1, fibronectin, ALK5, and β-catenin) by Western blot analysis. Results: Markers of alveolar epithelial/mesenchymal maturation (PPAR-γ, SP-C, CCT-α, and triolein uptake) increased significantly in the PGZ + B-YL group, more than with either drug alone. Similarly, markers of hyperoxia-induced lung injury were blocked effectively with PGZ + B-YL treatment. Conclusions: Nebulized PPAR-γ agonist PGZ with a synthetic lung surfactant accelerates lung maturation and prevents neonatal hyperoxia-induced lung injury more than either modality alone, with the potential to provide more effective prevention of BPD.
Introduction
Despite improvements in perinatal care, bronchopulmonary dysplasia (BPD) in extremely premature infants has not decreased [1, 2] . The postnatal use of surfactant provides symptomatic relief from respiratory distress syndrome (RDS), but it does not translate into a reduction in BPD. This is not surprising, since the administra-Neonatology 2018;113:296-304 DOI: 10.1159/000486188 tion of surfactant alone does not address the fundamental issue in RDS, i.e., lung immaturity [3, 4] . In contrast, PPAR-γ agonists recapitulate the natural cellular and molecular pathways that determine normal lung structure, function, and homeostasis. In multiple in vitro and in vivo experimental models of neonatal lung injury, PPAR-γ agonists, administered either parenterally [5] or locally [6] , enhance lung maturation and prevent neonatal lung injury [5] [6] [7] . We reasoned that combining lung surfactant with a PPAR-γ agonist would mean they complement each other's benefits, and that the net effect on lung injury reduction would be greater than with either intervention alone. Therefore, we hypothesized that a combined PPAR-γ agonist and surfactant formulation effectively blocks neonatal lung injury and that this effect is greater than with either modality alone.
We used a new and innovative surfactant protein B (SP-B) peptide mimic, B-YL, developed for aerosolized delivery specifically in a hyperoxic environment. Using the N-terminal (residues 1-25) and C-terminal (residues 63-78) α-helical sequences of native SP-B, connected with a short β-sheet loop [8] , we replaced the cysteine and methionine residues with tyrosine and leucine, respectively, to minimize inactivation by oxidative stress. Based on homology templating of the linear amino acid sequence (NH2-FPIPLPYYWLYRALIKRIQALIPKGGRL LPQLVY RLVLRYS-COOH), the 3-dimensional structure of the SP-B peptide mimic B-YL is shown in Figure  1 . As for the choice of PPAR-γ agonist, due to the proved superior safety and efficacy of nebulized pioglitazone (PGZ) in blocking hyperoxia-induced neonatal lung injury [5] , this was combined with B-YL surfactant. Using a neonatal rat model, we planned to administer a highly effective, stable, and oxidation-resistant synthetic lung surfactant, B-YL, and simultaneously enhance lung maturation via PGZ to prevent hyperoxia-induced neonatal lung injury.
Materials and Methods
Synthetic Surfactant B-YL peptide was synthesized on a Symphony multiple peptide synthesizer (Protein Technologies, Tucson, AZ, USA) using a FastMoc TM protocol on an H-Ser(OtBu)-HMPB NovaPEG resin, as described previously [8, 9] . Purified B-YL peptide was freeze-dried and its mass was confirmed by MALDI-TOF mass spectrometry. B-YL surfactant was formulated to contain 35 mg/mL of 5: 3: 2 DPPC:POPC:POPG combined with 3.0% (by wt) of B-YL. The synthetic surfactant components were combined in organic solvent (e.g., chloroform for lipids and TFE for peptide), dried under nitrogen, exposed to house vacuum to remove residual solvent, resuspended by hand-vortexing in 0.15 M NaCl adjusted to pH 7.0, heated to 65 ° C intermittently for 30 min, and refrigerated for > 12 h prior to use. PGZ was mixed into the surfactant as an ethanol suspension (4 mg/mL pure ethanol), followed by removal of the ethanol by evaporation. The surface tension-lowering ability of surfactant preparations was assessed under dynamic compression at 37 ° C by captive bubble surfactometry [8] . We routinely analyzed surfactant samples of 1 μL (35 mg phospholipids/mL) in approximately 1.5 mL of Goerke buffer with 10% sucrose (approx. 25 μg surfactant/ mL) in the captive bubble surfactometer, and performed all measurements in quadruplicate. Lipids only were used as a negative control and the clinical surfactant Infasurf ® as a positive control.
Animal Protocol and Study Design
All studies were approved by the Institutional Review Board and conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Briefly, following our previously described protocol, 1-day-old breastfeeding (ad libitum) rat pups were exposed to either normoxia (21% O 2 ) or hyperoxia (95% O 2 ) for 72 h [6, 7] . Hyperoxia-exposed animals were administered diluent, B-YL (100 mg/kg body weight [BW]), PGZ (1 mg/kg), or PGZ (1 mg/kg) + B-YL (100 mg/kg) in a 1-mL volume via nebulization over 30 min every 24 h for up to 72 h. Aerosolization of B-YL and PGZ was achieved with a vibrating mesh nebulizer (Aeroneb Pro ® nebulizer, Aerogen Inc., Mountain View, CA, USA) [9, 10] , which aerosolizes liquid formulations without affecting a compound's composition and concentration. This small-volume (10 mL maximum), median-diameter nebulizer delivers a low-velocity aerosol with a particle size < 3.0 μm and a flow rate > 0.1 mL/min, is FDA-approved for human use, and does not need a gas source [11] . Control (normoxia group) pups were administered the diluent similarly via nebulization.
All pups were killed at 72 h, and lungs were either snap-frozen for Western blot analysis of markers of lung homeostasis (SP-C and choline-phosphate cytidylyltransferase [CCT]-α levels) and injury repair (LEF-1 and fibronectin levels) or cultured as explants to determine the rate of [ 3 H] triolein uptake, a functional marker of surfactant phospholipid synthesis. A separate set of animals was used for bronchoalveolar lavage fluid (BALF) collection. Retrieved BALF was centrifuged at 400 g for 10 min. Sediments were analyzed for total cell counts and supernatants were snap-frozen in liquid nitrogen for the subsequent analysis of inflammatory markers, such as interleukin (IL)-6 and interferon (IFN)-γ (ELISA kits from R&D Systems).
Western Blot Analysis
Following previously described methods [6, 7, 12] , Western blot analysis was performed on lung tissue to determine the protein levels of markers of alveolar epithelial (SP-C and CCT-α) and alveolar mesenchymal (PPAR-γ) differentiation and injury repair (LEF-1 and fibronectin). Primary antibodies used included: PPAR-γ (1: 500), SP-C (1: 250), CCT-α (1: 200), LEF-1 (1: 200), fibronectin (1: 250), Bax (1: 500), Bcl-2 (1: 200) (all from Santa Cruz Biotechnology, Dallas, TX, USA), and GAPDH (1: 10,000; Millipore, Billerica, MA, USA).
Immunofluorescence
Tissue immunofluorescence staining for ALK5 (1: 100) and β-catenin (1: 100) was performed following previously described methods [7] .
Real-Time qRT-PCR for Lung Cytokine Assay
Tissue RNA extraction and q-RT-PCR were performed according to previously described methods [5] . RT-PCR primers used included IL-6: F 5′-CTTCCTACCCCAACTTCCAA-3′ and R 5′-ACCACAGTGAGGAATGTCCA-3′ (191 bp) and IFN-γ: F 5′-CCAAGTTCGAGGTGAACAAC-3′; R 5′-ACTCCTTTTCC-GCTTCCT-3′ (110 bp). The normalization control was 18S ribosomal RNA. The relative fold-change for each gene was calculated using the ΔΔCT method.
Choline Incorporation in Saturated Phosphatidylcholine Assay
[ 3 H]choline (NEN Dupont, Boston, MA, USA) incorporation into saturated phosphatidylcholine, which is the major surfaceactive lipid substrate of surfactant, was determined in cultured lung explants following our previously described protocol [12] .
Triglyceride Uptake Assay
[ 3 H]triolein (PerkinElmer, Boston, MA, USA) uptake, a key marker of alveolar lipofibroblast (LIF) function, was used to quantitate triglyceride uptake in fetal rat lung explants using our previously described protocol [12] .
Statistical Analysis
The Student t test and ANOVA, in combination with the Tukey post hoc test, as appropriate, were used to detect group differences. The number of samples for each analysis was 4-6, from 3 separate sets of experiments. Results are expressed as means ± SEM.
Results
We first determined whether combining PGZ with B-YL surfactant affects B-YL's bioactivity, by measuring its surface activity with captive bubble surfactometry [8, 10, 13] in the presence and absence of PGZ (B-YL [100 mg/kg] and PGZ [1 mg/kg]). We then compared this with a clinical surfactant (Infasurf) as a positive control and lipids only (DPPC:POPC: POPG 5: 3: 2 wt:wt:wt) as a negative control. Clinical surfactant contains both SP-B and SP-C, in contrast to B-YL that only contains a highly active SP-B peptide mimic. Minimum surface tension values of B-YL ± PGZ were similar to those of Infasurf (Fig. 2) .
Based on the ampholytic properties, the addition of B-YL to a prostaglandin agonist is not expected to interfere with PGZ's PPAR-γ agonist activity [14] . Therefore, we next confirmed that the addition of B-YL to PGZ did not interfere with its PPAR-γ agonist activity, and, hence its lung maturation effect. Embryonic day 19 fetal rat lung explants were cultured for 24 h with or without B-YL (100 mg/kg fetal BW) alone or with PGZ (0.5, 1, or 2 mg/kg BW). Following this, PPAR-γ, SP-C, and CCT-α protein levels, along with choline incorporation into disaturated phosphatidylcholine (DSPC), all markers of lung maturation, were determined. Explants treated with PGZ + B-YL demonstrated the expected increases in PPAR-γ, SP-C, and CCT-α protein levels (Fig. 3a) , and an increase in choline incorporation into DSPC (Fig. 3b) , indicating that combining B-YL with PGZ does not affect PGZ's lung maturation activity.
Having confirmed that combining B-YL and PGZ does not interfere with surface tension reduction and lung maturational activity (of B-YL and PGZ, respectively) under in vitro conditions, we next determined if this combined approach prevents hyperoxia-induced neonatal lung injury under in vivo conditions. Postnatal day 1 rat pups were exposed to either normoxia or hyperoxia for up to 72 h. Hyperoxia-induced decreases in PPAR-γ, SP-C, and CCT-α and increases in LEF-1 and fibronectin protein levels were blocked by the concomitant administration of either PGZ or PGZ + B-YL (Fig. 4a-e) . This was true also for the hyperoxia-induced decrease in triolein uptake (Fig. 4f) . As demonstrated by the effects on the protein levels of SP-C and CCT-α, and triolein uptake, PGZ + B-YL administration had a more robust effect. In contrast, B-YL administration alone had no effect on any of these parameters.
Blockage of hyperoxia-induced neonatal lung injury with combined PGZ + B-YL nebulization was also shown by the normalization of hyperoxia-induced alterations in the BALF cell count, the protein content, the whole-lung apoptosis marker (the Bcl-2/Bax ratio), and the lung inflammatory markers IL-6 and IFN-γ (Fig. 5) . Interestingly, even though B-YL administration alone did not have any effect on most of the molecular markers of lung maturation and injury repair, it did suppress the hyperoxiainduced increase in IL-6 and IFN-γ expression. Lastly, since hyperoxia-induced neonatal lung injury has previously been shown to be mediated by the activation of TGF-β and Wnt pathways, lung sections from the control, hyperoxia, and hyperoxia + PGZ + B-YL groups were stained for ALK5 and β-catenin, 2 key intermediates of TGF-β and Wnt pathway activations, respectively. In line with the data on other markers of lung injury, a hyperoxia-induced increase in ALK5 and β-catenin staining was blocked in the PGZ + B-YL group (Fig. 6 ). 
Discussion
Using both in vitro and ex vivo studies, we found that combining PGZ with the SP-B mimic B-YL does not interfere with the activity of PGZ and the surface tension-lowering activity of B-YL. Furthermore, in a neonatal rat model of hyperoxia-induced lung injury, the components of the nebulized formulation, PGZ and B-YL, complemented each other's benefits. This was reflected by the greater net reduction in lung injury than with one component or the other. For example, upon hyperoxia exposure, there was relatively greater preservation of the alveolar homeostatic markers PPAR-γ, SP-C, CCT-α, and the triolein uptake, suggesting potentially greater protection against hyperoxia-induced neonatal lung injury with the PGZ + B-YL formulation than with either component alone.
Prematurity is the underlying cause of lung immaturity leading to RDS. Various approaches including the administration of antenatal steroids, exogenous surfactant, and noninvasive and gentler modes of ventilation have shown only limited benefits in preventing RDS and BPD.
Only antenatal steroid therapy has been consistently shown to enhance lung maturation and decrease the incidence and severity of RDS. However, it is differentially more effective in females [15, 16] , is associated with significant side effects, and does not result in a reduction in BPD. In contrast, in experimental models, the administration of PPAR-γ agonists has been shown to reduce lung injury and enhance fetal/neonatal lung maturation safely in both males and females [17, 18] .
One of the biggest impediments towards finding an effective preventive/therapeutic intervention against BPD has been a failure to target the fundamental cellular and molecular pathways centrally involved in lung development and injury repair [3] . Combining surfactant with a PPAR-γ agonist aims to not only reduce the manifestations of RDS acutely, but to also recapitulate the natural cellular and molecular pathways that (i) determine the normal lung structure, function, and homeostasis; (ii) are disrupted by oxotrauma, inflammation, and volutrauma; and (iii) have been shown to be normalized by PPAR-γ agonists in multiple in vitro and in vivo models [4] [5] [6] [7] 18 ]. This approach is based on the paradigm that the developing lung mesenchyme, dominated by Wnt signaling, i.e., the default pathway for muscle development, inhibits C/ EBP-α and PPAR-γ, thereby actively inhibiting the adipogenic programming of the developing alveolar mesenchyme [19] . During lung morphogenesis, the mesenchymal default Wnt pathway is inhibited and the adipogenic pathway is disinhibited, resulting in the formation of lipid-laden alveolar interstitial adepithelial fibroblasts/LIFs [19] . LIFs are critical for lung homeostasis and injury repair, since they actively provide triglyceride substrate to ATII cells for surfactant synthesis, support ATII cell growth and differentiation, and act as an important defense against oxidative lung injury [19, 20] . Upon exposure to volutrauma, oxotrauma, and infection, pulmonary LIFs transdifferentiate to a myogenic phenotype, myofibroblasts [18, 21] . Myofibroblasts do not support ATII cell growth or differentiation, whereas LIFs do [20] , hence the critical importance of maintaining the proper balance of both, in order to direct lung development. Previous studies have demonstrated that all of the abovementioned BPD inducers cause the downregulation of alveolar LIF PPAR-γ expression [18] , and thus inhibit normal lung development, but that PPAR-γ agonists mitigate, and, in some cases, even reverse the lung damage [18, [20] [21] [22] . However, it is important to point out that although we have focused on the role of PPAR-γ in LIF biology, it also exerts a prominent injury repair effect via a variety of other mechanisms [23] .
Other advantages of our approach include the potential delivery of the nebulized PGZ + B-YL formulation directly to the lung, which should result in the maximum therapeutic effect, limit systemic side effects, and circumvent the issues pertaining to bioavailability and first-pass metabolism if administered orally. Furthermore, the aerosolized delivery of PGZ + B-YL eliminates intubation and associated complications. However, detailed pharmacokinetics studies are needed to determine the biodistribution of PGZ and B-YL in the lung, blood, and other organs as well as any systemic effects, before this proposed approach can be translated to the bedside.
As alluded to above, B-YL is an innovative surfactant developed specifically to resist hyperoxia-induced inactivation [24] . It is both stable and highly active in its native state and after the addition of PGZ during in vitro testing (Fig. 2) . Moreover, it has a low viscosity, aerosolizes easily, and can be produced inexpensively, all highly relevant attributes for its translation into clinical practice. Since the PGZ + B-YL formulation effectively blocked lung injury, even following an extremely high O 2 exposure, i.e., 95% O 2 exposure for 72 h (a scenario which is rarely used in contemporary neonatal practice), we are confident that it will also be effective against the usual lower levels of hyperoxia exposure frequently encountered in neonatal intensive care units. While PGZ was used as a prototype PPAR-γ agonist in this study, other PPAR-γ agonists might prove to be safer and even more effective. It is also worth noting that the lung maturational effect of PPAR-γ agonists is not restricted to PGZ, but has also been seen with curcumin, troglitazone, rosiglitazone, and prostaglandin J 2 [4-7, 18, 21, 25] .
